Docoh
Loading...

BMY Bristol-Myers Squibb

Filed: 4 Feb 21, 8:04am
0000014272bmy:CommonStock0.10ParValueMember2021-02-042021-02-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________________
FORM 8-K
_____________________________

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2021

_____________________________
BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)
_____________________________
Delaware001-0113622-0790350
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)(I.R.S Employer
Identification No.)
430 E. 29th Street, 14th Floor
New York, New York, 10016
(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (212) 546-4000
_____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.10 Par ValueBMYNew York Stock Exchange
1.000% Notes due 2025BMY25New York Stock Exchange
1.750% Notes due 2035BMY35New York Stock Exchange
Celgene Contingent Value RightsCELG RTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02 Results of Operations and Financial Condition.
On February 4, 2021, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the fourth quarter and full year of 2020. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Also furnished pursuant to this Item 2.02 as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein in its entirety is certain supplemental information posted on the Company’s website at www.bms.com.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:
Exhibit
No.
Description
99.1Press release of Bristol-Myers Squibb Company dated February 4, 2021.
99.2Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
EXHIBIT INDEX
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
BRISTOL-MYERS SQUIBB COMPANY
Dated: February 4, 2021By: /s/ Katherine R. Kelly
Name: Katherine R. Kelly
Title:Corporate Secretary